Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Refractory Multiple Myeloma

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is a potentially curative treatment for relapsed or refractory multiple myeloma (MM).
• Patient selection criteria often include age, fitness, and high-risk cytogenetic features.
• Optimizing pre-transplant conditions is crucial for improving allo-HSCT outcomes.

Purpose of the Study:

• To evaluate the impact of pre-transplant disease status on outcomes after allo-HSCT in multiple myeloma patients.
• To assess the relationship between response depth and survival, transplant-related mortality (TRM), and progression-free survival (PFS).

Main Methods:

• Retrospective analysis of medical data from 30 patients who underwent allo-HSCT between 2005 and 2020.
• Patients were categorized based on pre-transplant disease status: complete remission (CR), partial response (PR), progressive disease (PD), or stable disease (SD).
• Statistical analysis was performed to compare outcomes between groups with different response levels.

Main Results:

• Patients achieving CR or PR pre-transplant had significantly longer 5-year overall survival (OS) (45.8%) compared to those with less than PR (11.7%).
• Transplant-related mortality (TRM) at 100 days was significantly higher in patients with less than PR (100%) versus CR/PR (43.7%).
• Progression-free survival (PFS) was notably shorter for patients with less than PR (6.2 months) compared to those with CR/PR (77.1 months).

Conclusions:

• The depth of response prior to allo-HSCT is a critical factor influencing patient outcomes in multiple myeloma.
• Achieving at least a partial response before transplantation is associated with improved OS, reduced TRM, and prolonged PFS.
• Allo-HSCT can be a viable therapeutic option for relapsed/refractory MM patients, especially when a response is achieved post-initial therapy.